CTRI/2024/05/067631尚未招募4 期
A Prospective randomized controlled Open labelled two arm pilot study with blinded endpoints (PROBE) to evaluate the effect of Torsemide spironolactone vs Furosemide spironolactone combination in cirrhotic patientswith newly diagnosed ascites - nil
Amrita school of Medicine0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1 Cirrhosis diagnosed by imaging and or biopsy with newly diagnosed ascites with Ascitic fluid Protein less than 2.5g per dL, SAAG more than 1.1
- •2 Cirrhosis as evidenced by USG or Cross-Sectional imaging
- •3 Serum Creatinine less than 1.5mg per dl
- •4 Informed consent
排除标准
- •1 Spontaneous bacterial peritonitis
- •2 Pregnancy
- •3 Serum Creatinine more than 1.5 mg per dl
- •4. Urine albumin is to Creatinine ratio more than 500mg per gm creatinine
- •5 Poorly controlled diabetes, fasting glucose more than 200mg per dl
- •6.SIADH, as per Bartter Schwartz criteria
- •7.Anuria, urine volume less than 100ml per day
- •8.Cerebrovascular accident within 30 days prior to the study medication.
研究者
相似试验
尚未招募
不适用
To compare between honey dressing, insulin dressing and normal saline dressing as to which dressing heals the wound faster.CTRI/2022/11/047284All India Institute of Medical Sciences, Nagpur
已完成
3 期
A randomized open-labelled controlled prospective study to investigate the effect of inactive iodine and lithium carbonate on radioiodine therapy in patients with Graves' diseaseGraves'diseaseJPRN-UMIN000001087Hiroshima University Hospital Department of Endocrinology and Metabolism120
尚未招募
3 期
To find the usefulness of physical therapy through phone to improve the physical condition of children suffering from Guillain Barre Syndrome.CTRI/2021/04/032538PGIMER
已完成
4 期
Herbal product Clinical trial on COVID-19 patientsCTRI/2020/05/024967MiLab LifeSciences P Ltd42
进行中（未招募）
1 期
Clinical trial to evaluate the patient preference for therapy with everolimus in combination with exemestane or capecitabine in combination with bevacizumab in patients with advanced (inoperable or metastatic) breast cancerEUCTR2013-005329-22-DEiOMEDICO AG77